Evidence map›Paper›PMID 41877664›Full record

ArticleJournal of Alzheimer's disease : JAD2026

Disease modifying treatments for Alzheimer's disease: Clinician perspectives.

Catherine Pennington, Prathima Apurva, Ailin Chen, Alan Duncan, Graham Mackay, Hugh Masters, Katherine Paramore, Tom Russ, Helen Skinner, Martin Zeidler

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Catherine PenningtonDepartment of Neurology, NHS Forth Valley, Larbert, UK.ORCID 0000-0003-0675-9619
Prathima ApurvaNHS State Hospitals Board for Scotland, Carstairs, Lanark, UK.
Ailin ChenBrain Health Scotland (part of Alzheimer Scotland), Edinburgh, UK.
Alan DuncanOlder Adult Psychiatry, NHS Dumfries & Galloway, Dumfries, UK.
Graham MackayDepartment of Neurology, NHS Grampian, Aberdeen, UK.
Hugh MastersBrain Health Scotland (part of Alzheimer Scotland), Edinburgh, UK.
Katherine ParamoreDepartment of Neurology, NHS Fife, Cupar, UK.
Tom RussCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
Helen SkinnerBrain Health Scotland (part of Alzheimer Scotland), Edinburgh, UK.ORCID 0009-0000-6745-4953
Martin ZeidlerDepartment of Neurology, NHS Fife, Cupar, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years there have been exciting developments in the diagnosis and treatment of mild cognitive impairment and dementia due to Alzheimer's disease. Robust biomarkers and potentially disease modifying therapies are now available, with multiple other agents in clinical trials alongside on-going validation studies of blood-based biomarkers. Recent and probable future developments in the diagnosis and care of people with Alzheimer's disease pathology warrants serious re-evaluation of the structure and function of cognitive clinical services. Here we report recommendations from the November 2024 Brain Health Scotland roundtable discussion of opportunities and challenges for modern memory services.

Indexed as

Alzheimer DiseaseCognitive DysfunctionBiomarkersHumansBiomarkersAlzheimer's diseasebrain healthmild cognitive impairment

Identifiers

PMID41877664
PMCPMC13144632

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.